Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2023-03-15 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene to present at NWR Virtual Healthcare Conference 2 pages 114.8KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement about Imugene Limited presenting at the NWR Virtual Healthcare Conference. It includes details about the presentation date, time, and how to register or access the recording. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other regulatory filings. The document is short (3170 characters) and serves as an announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. Therefore, it fits best into the category of Investor Presentation (IP) announcements, as it informs investors about a forthcoming presentation focused on company strategy and market position.
2023-03-15 English
Imugene Corporate Presentation 32 pages 6.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Imugene Limited, a biotech company, focusing on their cancer immunotherapy pipeline, clinical trials, partnerships, and scientific background. It includes investment highlights, technology platforms, clinical trial phases, and profiles of key personnel. The content is structured as a presentation with slides, images, and detailed explanations of the company's strategy and products. There is no indication that this is a regulatory filing, earnings release, or annual report. The document is clearly an investor-focused presentation, likely used in a roadshow or investor meeting to communicate the company's business and scientific progress. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-03-14 English
Application for quotation of securities - IMU 11 pages 37.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities issued under an employee incentive scheme by Imugene Limited. It details the number and type of securities to be quoted, issue dates, prices, and compliance with ASX Listing Rules. There is no financial performance data, earnings information, or management discussion. The document is a formal announcement related to capital changes, specifically the issuance and quotation of new shares under an employee incentive scheme. This fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement or a report publication notice but a detailed filing about share issuance and quotation.
2023-03-09 English
Notification regarding unquoted securities - IMU 10 pages 35.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted options under an employee incentive scheme by Imugene Limited. It includes specifics such as the number of securities issued, issue dates, security descriptions, and references to ASX listing rules. The content focuses on the announcement of new securities issued, not on financial results, management changes, or other report types. The document is about the issuance of new securities, which aligns with announcements related to share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief announcement but a full notification of share issuance.
2023-03-09 English
Notice Under Section 708A 1 page 104.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 10 March 2023, titled 'Notice Under Section 708A(5) of the Corporations Act 2001'. It details the issuance of ordinary shares by Imugene Limited without disclosure under Part 6D.2 of the Corporations Act, compliance with relevant provisions, and absence of excluded information. This is a regulatory notice about a share issue but does not describe the share issue itself in detail or financial results. The document is short (1214 characters) and serves as a formal notification under the Corporations Act. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising or capital structure changes, including notices of share issuance under regulatory provisions.
2023-03-09 English
Change of Registered Office 2 pages 126.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'Change of Registered Office' for Imugene Limited. It provides updated registered office details and contact information. There is no financial data, no discussion of financial results, no mention of shareholder votes, no legal proceedings, no capital changes, and no other report or presentation content. The document is a regulatory announcement about a change in company office address, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-03-07 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.